Passion and purpose to transform patient journeys in anxiety and depression.

Maggie FitzPatrick joined our Board of Directors in July 2021 and has served as Chair since October 2023. Ms. FitzPatrick is the founder of FitzPatrick & Co., a strategic consulting firm, and previously served in the C-Suite of Exelon, Johnson & Johnson, and Cigna. At Johnson & Johnson, she led a team of more than 500 professionals covering global markets across 60 countries. Ms. Fitzpatrick is widely recognized as an expert on corporate affairs and board optimization. She has extensive experience serving on non-profit and publicly traded company boards. In addition to serving as Chair of our Board, she is the lead director at AN2 Therapeutics (NASDAQ: ANTX). In 2023, she was named to the board advisory faculty of the National Association of Corporate Directors (NACD). Ms. Fitzpatrick began her career in public policy and government service. She holds an M.A. in Public Policy from The George Washington University and a B.A. degree in English and Policy Studies from Syracuse University. She is a graduate of the Harvard Business School board directorship program and is a NACD-certified director. She is a past trustee of The Mead Center for American Theater at Arena Stage and served as past Commissioner of the Washington, DC Commission on the Arts and Humanities.